GEMS Shooting At Moon In Women's Health Via Lunar Densitometry Buy
This article was originally published in The Gray Sheet
Executive Summary
GE Medical Systems is looking to expand its women's health business by applying its worldwide marketing resources to increase the reach of Lunar Corporation's densitometry and orthopedic imaging brands.
You may also be interested in...
GE Medical
Shareholders of Madison, Wisconsin-based Lunar Corp. will receive 0.322 shares of GE stock for each share of Lunar stock under terms of the firms' merger deal completed Aug. 8. Announced June 2, the agreement was valued at roughly $144 mil. A manufacturer of diagnostics for osteoporosis and metabolic bone disease as well as orthopedic surgery devices, Lunar will add $91 mil. in annual revenues to GE's $7 bil. Medical Systems business. GEMS hopes to accelerate Lunar's top-line growth above the single-digit pace of the overall bone densitometry market (1"The Gray Sheet" June 5, p. 13)
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.